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Abstract
Centrosomes play a crucial role in the maintenance of genome stability by orchestrating bipolar mitotic spindle for-
mation. The centrosome normally duplicates precisely once before mitosis in a process that is extensively regulated
by protein degradation including SKP1–Cullin 1 (CUL1)–F-box (SCF) E3 ubiquitin ligase activity. The core SCF compo-
nent CUL1 has recently been found to be required to suppress the formation of supernumerary centrosomes and
centrioles, the core-forming units of centrosomes. Here, we identify the CUL1-interacting protein cullin-associated
and neddylation-dissociated 1 (CAND1) as a novel centrosomal protein with a role in centriole duplication control.
CAND1 was found to synergize with Polo-like kinase 4 (PLK4), a master regulator of centriole biogenesis, in the induc-
tion of centriole overduplication. We provide evidence that CAND1 functions in this process by increasing PLK4 pro-
tein stability. Furthermore, mutants of CUL1 that lack the ability to interact with CAND1 and are unable to assemble
functional E3 ubiquitin ligase complexes were impaired in their ability to restrain aberrant daughter centriole synthesis.
To corroborate a role of CAND1 in human carcinogenesis, we analyzed a series of prostate adenocarcinomas and
found altered expression of CAND1 on the mRNA or protein level in 52.9% and 40.8%, respectively, of the tumor
samples analyzed. These results highlight the role of altered SCF components in cancer in general and encourage
further studies to explore the SCF-CAND1 axis for the development of novel predictive biomarkers and therapeutic
approaches in prostate cancer.
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Introduction
Aneuploidy is a frequent finding in human cancer and commonly asso-
ciated with aggressive tumor phenotypes and malignant progression.
Several mechanisms can cause aneuploidy, and in particular, centrosome-
mediated cell division errors are believed to play an important role [1,2].
Centrosomes are the major microtubule-organizing centers of most
mammalian cells, both during interphase and mitosis [3]. They consist
of a pair of centrioles, short barrel-shaped microtubule cylinders, em-
bedded in pericentriolar material [4]. The single centrosome of a non-
dividing cell duplicates precisely once before mitosis to produce two
centrosomes that function as mitotic spindle poles to determine spindle
bipolarity and orientation. Cancer cells frequently show aberrant centro-
some numbers leading to mitotic spindle abnormalities and chromosome
missegregation [5,6]. Precise control of centrosome duplication is hence
pivotal for the maintenance of genome integrity during mitosis.
Centrosome duplication is initiated by disengagement of the two
preexisting (maternal) centrioles by the coordinated action of Polo-like
kinase 1 (PLK1) and separase [7]. Daughter centriole formation is
then triggered by the recruitment of PLK4 to the wall of maternal cen-
trioles through interaction with another centriolar protein, CEP152
[8–10]. It has previously been shown that tight regulation of PLK4
by SKP1–Cullin 1 (CUL1)–F-box (SCF) E3 ubiquitin ligase activity
and proteasomal degradation is essential to prevent the synthesis of
extra daughter centrioles [11]. CUL1 has recently been reported to
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suppress centriole multiplication, a process where a single maternal
centriole assembles multiple daughters concurrently [12].
CUL1 is one of seven human cullins that assemble into cullin–
RING E3 ubiquitin ligases (CRLs). It functions as a scaffold protein
and interacts with SKP1 at its amino-terminus to recruit a substrate-
binding protein (F-box–containing protein) and with RBX1, a RING-
domain protein, at its carboxy-terminus to facilitate interaction with
an E2 ubiquitin–conjugating enzyme. The various F-box proteins that
have been identified to date are responsible for substrate recognition
and binding by the complex and hence provide specificity to the poly-
ubiquitination process and ultimately targeted protein degradation by
the proteasome [13].
Besides this modular organization of most CRLs, a number of regu-
latory factors have been identified. All cullins can be post-translationally
modified by the covalent attachment of the small ubiquitin-like pro-
tein NEDD8. Neddylation is associated with enhanced CRL activity,
whereas deneddylation, which is mediated by the COP9 signalosome,
decreases CRL activity. In addition, the cullin-interacting protein cullin-
associated and neddylation-dissociated 1 (CAND1) has been identified
to play a role in modulating CRL activity [14,15].
CAND1 is a 120-kDa HEAT repeat–containing protein that inhibits
the assembly of multi-subunit E3 ubiquitin ligase complexes. CAND1
only binds unneddylated and, hence, inactive CUL1 and competes with
SKP1 for binding to CUL1, thereby generally suppressing SCF ubiquitin
ligase activity [14–16]. However, CAND1 has also been reported to be
required for CRL function in certain model organisms in vivo [17,18].
These contradictory findings have been, at least in part, reconciled by
two results. First, it was shown that expression of CAND1 can prevent
substrate adapter autoubiquitination [15,19]. Second, CAND1 bind-
ing and dissociation was found to promote the assembly and disassem-
bly of SCF complexes, thereby stimulating the activity of certain SCF
complexes, as opposed to a global inhibition [20,21].
Here, we show that CAND1 is a centrosomal protein that controls the
stability of PLK4, a master regulator of centriole biogenesis. CAND1 was
found to synergize with PLK4 to stimulate centriole overduplication and
we provide evidence that CAND1 expression is disrupted on both the
mRNA and protein levels in a substantial fraction of prostate cancers. These
findings underscore the important role of regulators of CRL activity in
human cancer in general and encourage further studies for the develop-
ment of novel biomarkers and therapeutic approaches in prostate cancer.
Materials and Methods
Cell Culture and Transfections
U-2 OS/centrin-green fluorescent protein (GFP) cells (centrin-GFP
construct kindly provided by Michel Bornens, Institut Curie, Paris,
France) [22] were cultured and transiently transfected as previously de-
scribed [12]. Plasmids used for cell transfections were myc-tagged
CAND1, hemagglutinin (HA)-tagged wild-type CUL1 or HA-tagged
mutant CUL1-ΔN53 or CUL1-ΔC22 (kindly provided by Yue Xiong,
University of North Carolina, Chapel Hill, NC), or myc-tagged PLK4
(kindly provided by Erich A. Nigg, Biocenter, University of Basel, Basel,
Switzerland). Cells were plated onto 60-mm tissue culture dishes and
transfected with 2 μg of plasmid DNA using lipofection (FuGENE 6,
Roche, Basel, Switzerland) unless indicated otherwise.
Immunologic Methods
Cells were grown on coverslips and processed for immunofluorescence
analysis as previously described [23]. For pre-extraction, slides were
immersed in 1% Triton-X for 12 minutes before paraformaldehyde
fixation. Antibodies used were directed against CAND1 (H-85, rabbit
polyclonal directed against amino acid residues 396–480, Santa Cruz,
Santa Cruz, CA; or 5D7, mouse monoclonal directed against amino
acid residues 1–100; Abnova, Taipei, Taiwan), CEP170 (Invitrogen,
Camarillo, CA), orCUL1 (SantaCruz; all at a 1:50 dilution). Rhodamine
Red–conjugated secondary antibody or Cyan Fluorescent Protein–
conjugated secondary antibody was used (Jackson Immunoresearch,
West Grove, PA).
Immunohistochemical stainings of benign or malignant pros-
tate specimens for CAND1 or CUL1 were performed using a com-
mercially available tissue microarray (US Biomax, Rockville, MD).
Briefly, sections were deparaffinized in xylene, rehydrated in a graded
ethanol series, and boiled in a microwave oven for 30 minutes in a
citrate buffer (pH 6.0) followed by blocking and incubation with
primary antibodies against CAND1 (5D7, Abnova, at a 1:50 dilution)
or CUL1 (Ab-1, Lab Vision, Kalamazoo, MI, at a 1:200 dilution).
Immunoperoxidase detection of primary antibodies was performed
using the Histostain-Plus Kit (Invitrogen) according to the manu-
facturer’s recommendations.
For immunoblot analysis, whole protein extracts were obtained
as previously described [23]. Immunoblot analysis was performed
using antibodies against HA-tag (Covance, Princeton, NJ), myc-tag
(Cell Signaling, Dancers, MA), actin (Sigma-Aldrich, St Louis, MO),
or glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Santa Cruz).
To assess protein stability, we treated cells with 60 μg/ml cycloheximide
(CHX) for the indicated time intervals.
Quantitative Polymerase Chain Reaction
Quantitative polymerase chain reaction (qPCR) analysis of nine nor-
mal and 31 cancerous prostate specimens for CAND1mRNA expression
was performed using the TissueScan Prostate Cancer cDNA Array III
(Origene, Rockville, MD). Total RNA obtained from pathologist-
verified tissues was normalized and validated with β-actin in two se-
quential qPCR analyses by the manufacturer. cDNAs were resuspended
according to the manufacturer’s protocol. qPCR was performed using
specific primers to CAND1 (forward: 5′-GCTGATATGTTGAGC-
AGGCAA-3′, reverse: 5′-ACTGGGGAAGTAGACAGGTCA-3′;
IDT, Leuven, Belgium) and measured using the SsoFast EvaGreen
Kit (Bio-Rad, Hercules, CA) according to the manufacturer’s pro-
tocol. Cycling conditions were 95°C (30 seconds, activation), 95°C
(5 seconds, denaturation), and 60°C (10 seconds, annealing/extension)
for 40 cycles on a Bio-Rad CFX96 Real-Time System run on a C1000
Thermal Cycler (Bio-Rad). Threshold for Cq determination was set
according to the manufacturer’s protocol. Relative fluorescence units
are given.
Flow Cytometry
Cells were analyzed for cell cycle distribution after propidium iodide
staining using a FACSCalibur flow cytometer (Becton Dickinson,
San Jose, CA).
Statistical Analysis
Student’s two-tailed t test for independent samples and Fisher’s Exact
Probability test (two-tailed) were used wherever applicable. All centriole
quantification experiments were performed at least as three independent
experiments with at least 100 cells counted per experiment.
800 CAND1 and Prostate Cancer Korzeniewski et al. Neoplasia Vol. 14, No. 9, 2012
Results
CAND1 Colocalizes with CUL1 at the Centrosome
On the basis of the role of CAND1 as CUL1-interacting protein
and the finding that CUL1 is a centrosomal protein, we asked first
whether CAND1 may localize to the centrosome. A predominantly
centrosomal localization of CAND1 together with a weak nuclear
staining was detected in pre-extracted U-2 OS cells stably expressing
centrin-GFP (Figure 1A). Without pre-extraction, CAND1 showed
a nucleocytoplasmic localization in line with previous findings [24].
Using a second antibody directed against a different epitope, we con-
firmed the centrosomal localization of CAND1 and found CAND1 to
colocalize with CUL1 at the centrosome by coimmunofluorescence
microscopy (Figure 1B). Similar to CUL1 [12], CAND1 was found
to localize predominantly to mature maternal centrioles as evidenced
by colocalization of CAND1 with CEP170 (Figure 1C ) and ninein
(not shown) [25,26]. The centrosomal localization of CAND1 was
dependent on the presence of CUL1 because small interfering RNA
(siRNA)-mediated knockdown of CUL1 abolished CAND1 staining
(Figure 1D). This suggests that CUL1 may be the predominant centro-
somal binding partner of CAND1. CAND1 was found to localize to
centrioles throughout the cell division cycle (Figure 2). In addition, we
found that the second mature centriole, which is present in the G2 phase
of the cell division cycle, also acquires CAND1 staining (Figure 2).
On the basis of the idea that CAND1 has, in general, inhibitory
activities on the assembly of active SCF E3 ubiquitin ligase complexes,
we asked whether ectopic expression of CAND1 can induce centriole
multiplication, which has been reported previously in cells in which
CUL1 was inhibited, for example, by siRNA or a dominant-negative
(DN) CUL1 mutant [12]. We found that transient overexpression of
CAND1 led to only a modest increase of U-2 OS/centrin-GFP cells
with centriole overduplication (defined as more than four centrioles
Figure 1. CAND1 is a centrosomal protein and colocalizes with CUL1. (A) Immunofluorescence microscopic analysis of CAND1 using a
monoclonal antibody against CAND1 (5D7) in U-2 OS/centrin-GFP cells with pre-extraction (top panels) or without pre-extraction (bottom
panels). (B, C) Coimmunofluorescence microscopic analysis of CAND1 and CUL1 (B) and CAND1 and CEP170 (C) in U-2 OS/centrin-GFP
cells. A second, polyclonal antibody (H-85) is used. (D) Immunofluorescence analysis of CAND1 (antibody 5D7) in U-2 OS/centrin-GFP
cells transfected with either control siRNA or siRNA targeting CUL1. Note the loss of CAND1 expression at centrioles in CUL1-depleted cells.
All arrows point at the centrioles shown in insets. All scale bars, 10 μm.
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per cell and at least one maternal centriole with more than one
daughter) from 0.5% in controls to 1.7% after 48 hours (P < .05,
Student’s t test for independent samples, two-tailed).
CAND1 forms a clamp around CUL1 to occupy the SKP1 binding
site at the N-terminus, whereas the CAND1 HEAT repeats interact
with the C-terminus, thereby blocking the CUL1 neddylation site
[16]. We therefore tested the effects of two CAND1 binding–deficient
CUL1 mutants, in which 53 residues from the amino-terminus
(ΔN53) or 22 residues from the carboxy-terminus (ΔC22) [27], respec-
tively, have been deleted, for effects on centriole overduplication (Fig-
ure 3, A and B). Both mutants showed an impaired ability to restrain
aberrant daughter centriole biogenesis at maternal centrioles when
compared to full-length CUL1 (Figure 3B). Transient overexpression
of CUL1-ΔC22 led to an increase of the proportion of cells with gen-
uine centriole overduplication from 0.25% in controls to 3.4% (P <
.05), whereas ectopic expression of CUL1-ΔN53 caused an increase
that did not reach statistical significance (3%; P > .05). The lack of
significant centriole overduplication in CAND1-expressing cells and
the moderate increase in cells overexpressing the two CUL1 deletion
mutants were not related to the fact that cells were in a nonpermissive
state because pretreatment with aphidicolin to induce an S phase arrest
could not increase centriole overduplication when compared to empty
vector controls (data not shown).
To address the question of how the CUL1mutants increase centriole
overduplication, we first performed a cell cycle analysis, but no signifi-
cant changes in the cell cycle distribution were detected (Figure 3C).
Because PLK4 has been identified as a key CUL1 substrate in cen-
triole duplication control, we analyzed PLK4 protein expression after
transient overexpression of CUL1 mutants followed by a 6-hour CHX
block to determine protein stability. We found that transient over-
expression of mutant CUL1-ΔN53 did not lead to increased PLK4
protein expression after 48 hours but that the mutant CUL1-ΔN53
stabilized PLK4 level after 6-hour CHX (Figure 3D). In contrast, over-
expression of CUL1-ΔC22 led to an increase of PLK4 protein expression
after 48 hours, but there was no significant stabilization detectable after
a 6-hour CHX block. Together, these findings suggest that CAND1
binding–deficient CUL1 mutants can induce a modest increase of cen-
triole overduplication that, at least for the C-terminal mutant CUL1-
ΔC22, involves up-regulation of the PLK4 protein.
CAND1 Synergizes with PLK4 to Induce Centriole
Overduplication through Enhanced PLK4 Protein Stability
Because the previous results suggest a role of PLK4 protein expres-
sion in the relaxation of centriole duplication control, we next asked
whether CAND1 may synergize with PLK4 to stimulate centriole
overduplication. We tested whether CAND1may modulate PLK4 func-
tion when both are coexpressed. For this experiment, we used the ability
of PLK4 to induce full centriole multiplication, i.e., “centriole flowers”
(Figure 3F ) [28,29], as experimental readout. When we transiently
overexpressed CAND1 in U-2 OS/centrin-GFP cells for 24 hours
and then transfected cells with increasing amounts of PLK4 plasmid
DNA for an additional 24 hours, we found that cells coexpressing
CAND1 and PLK4 showed significantly higher levels of centriole
multiplication than cells expressing PLK4 alone (10.7% vs 4.5% with
0.1 μg of PLK4 DNA transfected, P < .005 and 28.2% vs 13.1% with
0.5 μg of PLK4 DNA transfected, P < .001; Figure 3G ).
To further corroborate these results, we determined the protein
stability of PLK4 in the presence or absence of CAND1. Using a
6-hour CHX block experiment, we found that CAND1 overexpression
led to an increased protein stability of ectopically expressed PLK4
(Figure 3H). Taken together, these results show that although CAND1
is unable to stimulate a significant increase of cells with centriole
overduplication alone, it can significantly promote PLK4-induced
centriole overduplication.
CAND1 mRNA and Protein Expression Is Frequently
Disrupted in Prostate Cancer
In general, little is known about the role of CAND1 in human
tumorigenesis [24]. However, CAND1 has previously been shown to
be subject to microRNA (miRNA)-mediated regulation in a prostate
cancer cell line [30]. We therefore asked whether CAND1mRNA expres-
sion levels may be altered in a series of primary prostate adenocarcinomas.
Figure 2. CAND1 expression during the cell division cycle. Immunofluorescence microscopic analysis of CAND1 expression at different cell
cycle stages in asynchronously growing U-2 OS/centrin-GFP cells. All arrows point at the centrioles shown in insets. Scale bar, 10 μm.
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Figure 3. CAND1 stabilizes PLK4 and synergizes with PLK4 to induce centriole overduplication. (A) Immunoblot analysis of U-2 OS/
centrin-GFP cells for CUL1 and CUL1 deletion mutants. Immunoblot for actin is shown for protein loading. (B) Quantification of the per-
centage of U-2 OS/centrin-GFP cells with centriole overduplication (more than four per cell and at least one maternal centriole with more
than one 1 daughter) following transient transfectionwith empty vector (control), CUL1, or CUL1mutants. Mean and standard errors of three
independent experiments are shown. Asterisks indicate statistically significant differences (P < .05, Student’s t test for independent sam-
ples, two-tailed). (C) Cell cycle distribution after transient transfection of U-2 OS/centrin-GFP cells as assessed by flow cytometry. (D, E)
Immunoblot analysis of U-2 OS/centrin-GFP cells for PLK4 (anti-myc) or CUL1 mutants (anti-HA) 48 hours after transfection with PLK4-
myc, CUL1-ΔN53-HA or CUL1-CΔ22-HA transfection (0-hour CHX), or after 6-hour CHX block. GAPDH is shown to demonstrate protein
loading. (F) Fluorescence microscopic analysis of U-2 OS/centrin-GFP cells following transfection with either empty vector (control) or
PLK4. Note the concurrent formation of multiple daughter centrioles at single maternal centrioles (“centriole flower”), which is highly char-
acteristic for PLK4 overexpression (right panel). Scale bar, 5 μm. (G) Quantification of the percentage of U-2 OS/centrin-GFP cells with cen-
triole overduplication after transfection with PLK4 alone (open bars, μg of PLK4 plasmid DNA transfected as indicated) or in combination
with CAND1 (black bars). Mean and standard errors of three independent experiments are shown. Asterisks indicate statistically significant
differences (P< .005, Student’s t test for independent samples, two-tailed). (H) Immunoblot analysis of U-2 OS/centrin-GFP cells for CAND1
and PLK4 (anti–myc tag), CUL1 or actin after transient transfection of cells with empty myc tag vector (control), CAND1-myc, and/or PLK4-
myc and treatment of cells with CHX (60 μg/ml) for the indicated time intervals. Note the increased protein expression of PLK4 in cells
cotransfected with CAND1 after 6-hour CHX in comparison to the decreased protein expression when PLK4 is expressed individually.
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We performed a quantitative reverse transcription–PCR analysis of
nine normal and 31 cancerous prostate samples using a commercially
available qPCR gene expression array containing a series of normalized
and validated cDNA samples (Figure 4). The mean Cq for normal
prostate samples was 35.69 ± 1.23 (SD). Of the 31 prostate cancer sam-
ples, one tumor (3.2%) showed a Cq value greater than mean + 3 SD
(i.e., 39.38 cycles) indicating reduced mRNA expression in comparison
to controls, whereas 15 tumors (48.4%) showed a Cq value below
mean − 3 SD (i.e., 35.69 cycles) indicating increased mRNA expression
(Figure 4). These findings indicate that CAND1 is transcriptionally de-
regulated, predominantly upregulated, in a fraction of prostate cancers.
To further corroborate and extend these results, we performed an
immunohistochemical analysis of normal (n = 10), hyperplastic (n =
19), and malignant (n = 49) prostate specimens for CAND1 and
CUL1 using a commercially available tissue microarray (Figure 5).
Most normal and hyperplastic specimens show a weak-to-moderate
nucleocytoplasmic CAND1 staining (90% and 94.7%, respectively;
Figure 5, A and B), whereas adenocarcinomas showed a loss of CAND1
expression in 14.3% of tumors and overexpression in 26.5% of tumors.
CUL1 immunohistochemistry of an adjacent section of the tissue
microarray showed likewise a predominantly weak-to-moderate staining
in normal and hyperplastic specimens (80% and 78.9%, respectively;
Figure 5, A and B), whereas adenocarcinomas showed loss of expression
in 4.1% and an overexpression in 36.7% of tumors. The correlation
between an altered (loss or overexpression) CAND1 expression and
malignancy was statistically significant (P < .005), whereas the correla-
tion between altered CUL1 expression and malignancy did not reach
statistical significance (Figure 5B).
Discussion
The results presented here highlight a novel and important role of the
CRL regulatory protein CAND1 in centrosome duplication control
and cancer. Our findings provide evidence for a frequent disruption
of CAND1 expression on both the mRNA and protein level in prostate
cancer. When overexpressed in vitro, CAND1 had only little effect on
centriole biogenesis. However, we detected a pronounced synergistic
effect with PLK4, a master regulator of centriole biogenesis [29], on
aberrant centriole biogenesis. Mechanistically, we found that PLK4
protein was significantly stabilized when CAND1 was overexpressed.
These results suggest that overexpression of CAND1 may promote
malignant progression by stabilizing PLK4, thereby enhancing centro-
some overduplication and mitotic defects.
To corroborate the last point, we analyzed the 13 prostate cancer
samples with CAND1 overexpression and found that seven also
showed upregulated PLK4 expression (data not shown). We believe
that these data need to be confirmed in a more stringent fashion
and, importantly, on a cell-by-cell basis, but these preliminary data
point to an association between CAND1 expression and PLK4 protein
expression in cancer. Whether up-regulation of CAND1 leads to PLK4
accumulation simply through inhibition of its SCF-mediated ubiquitina-
tion or whether disruption of proper assembly and disassembly cycles
of CRLs as previously suggested [20,21] plays a role remains to be
determined (see also below).
A number of questions remain to be answered including why
CAND1 overexpression alone does not lead to centriole overduplica-
tion and how the C-terminal and N-terminal CUL1 mutants subvert
centriole duplication control.
CAND1 was only found to stabilize ectopically expressed PLK4
after a CHX block similar to mutant CUL1-ΔN53, which, in contrast
to CAND1, did increase centriole overduplication to a certain degree.
Mutant CUL1-ΔC22 was found to cause an increase of PLK4 already
at 48-hour post-transfection together with centriole overduplication.
There are a number of points that need to be taken into considera-
tion when interpreting these perplexing results. First, the overall level
of centriole overduplication is lower in CAND1- or CUL1 mutant–
expressing cells than what has previously been detected in cells trans-
fected with DN CUL1 mutant [12]. This makes it unlikely that
CAND1 simply functions as a CUL1 inhibitor that would lead to
a more pronounced increase of centriole overduplication. How-
ever, aberrant PLK4 protein levels after ectopic expression could
stimulate increased E3 ubiquitin ligase activity to counterbalance the
overabundance of PLK4. Under such conditions, increased CAND1
levels could impede SCF ubiquitin ligase assembly, thereby stabilizing
PLK4 and promoting centriole overduplication as shown here. The
presence of such feedback loops to control steady-state protein expres-
sion has recently become evident [31]. CAND1 can also have positive
Figure 4. Disruption of CAND1 mRNA expression in prostate cancer. qPCR analysis of nine normal and 31 cancerous prostate specimens
for CAND1 mRNA expression. Relative fluorescence units are given. Red amplification curves represent normal control tissue; blue
amplification curves represent prostate cancer samples.
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effects on E3 ubiquitin ligase assembly, but we believe that our results
in the overexpression scenario speak against this possibility, which
does not preclude this possibility under conditions where PLK4 is not
ectopically expressed.
With respect to the two CUL1 mutants, several additional aspects
also have to be considered. Both CUL1 deletion mutants fail to interact
with CAND1 [27]. This could, in theory and under the assumption
that CAND1 functions primarily as a CUL1 inhibitor, lead to a situa-
tion in which SCF complexes become “hyperactive” because of dis-
inhibition. This should lead to a reduced PLK4 expression and no
centriole overduplication or even suppression of this process. Never-
theless, we detected a moderate but reproducible and, in the case of
CUL1-ΔC22, even statistically significant induction of centriole over-
duplication. As mentioned above, binding to CAND1 can also posi-
tively influence E3 ubiquitin assembly and lack of binding could,
hence, impair protein degradation, which, at least for PLK4 levels
immediately 48 hours after transfection, is what our results show for
the C-terminal CUL1 mutant. Nonetheless, the N-terminal mutant
does stimulate centriole overduplication, albeit not in a significant
manner, but no increase of PLK4 at 48 hours after transfection level
is detectable.
To explain these apparent discrepancies, we need to discuss the fact
that these CUL1 mutants are defective in other ways as well. The
C-terminal sequence of CUL1 has been reported to be required for
its nuclear localization, and CUL1-ΔC22 was found to have a severely
reduced nuclear localization and to accumulate in the cytoplasm [27].
In addition, nuclear localization was found to promote CUL1 neddyla-
tion and full activation of its ubiquitin ligase activity [27]. The altered
subcellular abundance together with impaired ubiquitin ligase activity
of CUL1-ΔC22 could readily impact on the degradation of PLK4.
PLK4 is predominantly centrosomal, i.e., outside the nucleus, and rap-
idly accumulates at the centrosome when its degradation is abrogated
[12]. Hence, cytoplasmic mislocalization of CUL1-ΔC22 could rapidly
lead to increased PLK4 levels at 48 hours and before the CHX block.
Figure 5. CAND1 protein is overexpressed in a subset of prostate cancers. (A) Immunohistochemical analysis of benign prostate tissue
specimens and prostate adenocarcinomas for CAND1 or CUL1. Note the predominantly weak-to-moderate expression in the benign
tissue samples. Note the loss (top left panel of adenocarcinomas), weak-to-moderate staining (top right), or overexpression (bottom
panels) of CAND1 and CUL1, respectively, in prostate adenocarcinoma samples. Scale bar, 50 μm. (B) Overview of immunohistochemical
staining results.
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The N-terminal CUL1 deletion mutant can be expected to localize to
the nucleus and to become neddylated, yet it fails to bind SKP1 [14],
which associates with the N-terminus of CUL1. This could impact
the turnover of PLK4 protein after CHX block as shown in Figure 3D
similar to CAND1.
Why the N-terminal CUL1 mutant can still, to a certain degree,
albeit not in a statistically significant manner, induce centriole over-
duplication without an apparent PLK4 protein increase at 48 hours
after transfection is unclear. One possibility is that this mutant affects
the protein expression of cofactors for PLK4-induced centriole over-
duplication that are also targets of CUL1-mediated degradation with-
out apparent change of PLK4 total level, for example, cyclin E [12].
Future experiments will address this interesting possibility.
Regarding the mechanism of CAND1 up-regulation in prostate
cancer, we provide evidence that at least in some tumors altered gene
transcription may play a role. A previous study has shown that that
up-regulation of microRNA miR-148a can lead to a reduced CAND1
expression in a prostate cancer cell line [30]. Because some of the
tumors analyzed here show a loss of CAND1 mRNA and protein
expression, microRNA-mediated modulation of CAND1 expression
is a possibility that warrants further testing. Nevertheless, transcrip-
tional upregulation appears to be an important mechanism of CAND1
deregulation in primary prostate cancers.
Taken together, our results highlight a novel role of the CRL regu-
latory protein CAND1 in centriole duplication control and provide the
first evidence of its deregulation in a considerable proportion of primary
prostate adenocarcinomas. These findings underscore the frequent
disruption of CRL components in human malignancies [13]. Our
results also warrant further exploitation for the development of novel
predictive biomarkers and innovative therapeutic approaches to target
the SCF-CAND1 axis in prostate cancer.
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